Log in
ASX:KZA

Kazia Therapeutics Limited (KZA.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.40
MA: A$0.40
A$0.40
52-Week Range N/A
Volume47,736 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 9472 4101
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$988,110.00
Book ValueA$0.15 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Receive KZA News and Ratings via Email

Sign-up to receive the latest news and ratings for KZA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Kazia Therapeutics Limited (KZA.AX) (ASX:KZA) Frequently Asked Questions

Who are some of Kazia Therapeutics Limited (KZA.AX)'s key competitors?

Who are Kazia Therapeutics Limited (KZA.AX)'s key executives?

Kazia Therapeutics Limited (KZA.AX)'s management team includes the following people:
  • Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (, CEO, MD & Exec. Director (Age 47, Pay $738.46k)
  • Ms. Gabrielle Heaton, Director of Fin. & Admin.
  • Ms. Catherine Jane Hill B.Sc., C.A., ACA, GAICD, BSc (Hons), Company Sec. (Age 60, Pay $142.88k)
  • Kym Robins, Director of Marketing & Communications

What is Kazia Therapeutics Limited (KZA.AX)'s stock symbol?

Kazia Therapeutics Limited (KZA.AX) trades on the ASX under the ticker symbol "KZA."

How big of a company is Kazia Therapeutics Limited (KZA.AX)?

Kazia Therapeutics Limited (KZA.AX) has a market capitalization of $0.00 and generates $988,110.00 in revenue each year.

What is Kazia Therapeutics Limited (KZA.AX)'s official website?

The official website for Kazia Therapeutics Limited (KZA.AX) is www.kaziatherapeutics.com.

How can I contact Kazia Therapeutics Limited (KZA.AX)?

The company can be reached via phone at 61 2 9472 4101.

This page was last updated on 10/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.